Master of Bioethics (MBE)
Master of Health Care Innovation
ELSI Postdoctoral Training Fellowship
Master of Science in Medical Ethics (MSME)
Undergraduate Bioethics Minor
Fellowship in Advanced Biomedical Ethics
Continuing Education
Certificate Programs

Logo

 

 

Logo

News & Research
February 12, 2020 | Becker's Hospital Review

Risa Lavizzo-Mourey Celebrated As Top Medical Pioneer to Celebrate This Black History Month

Risa Lavizzo-Mourey, MD, MBA, has been named one of Becker's Hospital Review's 25 medical pioneers to celebrate this Black History Month.

Read More
February 12, 2020 | inewsource

The Navy SEAL and is doctor: An experimental brain treatment blows up 2 lives

REWIRED is a two-part inewsource investigation into a promising and experimental brain treatment that has sparked mayhem for the doctor who developed it and the Navy SEAL who had a psychotic break after receiving it.

Read More
February 11, 2020 | Scientific American

The Perils of “Survivorship Bias”

Say you walk into an emergency room, and you might or might not be having a heart attack. If I test you, I learn whether I’m making a good decision or not. But if I say, “It’s unlikely, so I’ll just send her home,” it’s almost the opposite of survivorship bias.

Read More
See All News
Events
February
18
1402 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104

Penn Bioethics Seminar | Moira Kyweluk, PhD, MPH

Learn More 2020-02-18 12:00:00 2020-02-18 13:00:00 America/New_York Penn Bioethics Seminar | Moira Kyweluk, PhD, MPH Testing “everyone for everything”: Ethical issues in expanded carrier screening   Using a basic saliva or blood sample, pregnant women or women intending to conceive are increasingly undergoing screening for serious, prevalent, and clinically-actionable recessive genetic conditions that could affect future offspring. The rapid expansion of inexpensive genetic sequencing technologies now allows screening for over 300+ conditions, some of which are extremely rare. In contrast to traditional carrier screening, which focuses on specific traits based on race/region or origin/ethnicity (e.g., screening for Tay Sachs in individuals of Ashkenazi Jewish and/or French Cajun ancestry) expanded carrier screening (ECS) tests “everyone for everything” without differentiating by patient origins or identity. Through qualitative interviewing and clinical observation, this project gathers empirical data on the experiences of patients, providers, and genetic counselors navigating ECS. The goal is to better understand the public health implications, interpersonal decisions, and ethical issues that this testing opens. This talk will present preliminary fieldwork from the pilot project at Penn Fertility Care, where patients are routinely screened using a commercially available product, the Foresight Carrier Screen (Myriad Labs). I will present the future directions of the project and consider some of the ethical and policy issues coming to light through these diagnostic services.     Moira Kyweluk, PhD, MPH Fellow, Medical Ethics and Health Policy University of Pennsylvania   1402 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 Penn Medical Ethics
February
25
1402 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104

Penn Bioethics Seminar | Sharrona Pearl, PhD

Learn More 2020-02-25 12:00:00 2020-02-25 13:00:00 America/New_York Penn Bioethics Seminar | Sharrona Pearl, PhD “Face/off or on: Face transplants and the resistance to categorization”   Sharrona Pearl, PhD Associate Teaching Professor of Medical Ethics Drexel University     1402 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 Penn Medical Ethics
March
2
Class of 1962 Auditorium, John Morgan Building (3620 Hamilton Walk)

Research Ethics and Policy Series (REPS) | Alison Bateman-House, PhD, MPH, MA

Learn More 2020-03-02 12:00:00 2020-03-02 13:00:00 America/New_York Research Ethics and Policy Series (REPS) | Alison Bateman-House, PhD, MPH, MA What Expanded Access and Right To Try Can and Cannot Do   The most common way for people in the United States to get access to investigational medical products is by participating in clinical trials. For patients who are unable to participate in clinical trials but who wish to try an experimental drug, device, vaccine, or other medical product, there are two pathways that permit non-trial access to products that are still in clinical development and not approved for any use. These are Expanded Access, which has existed for several decades, and Right to Try, which is much newer. Alison Bateman-House will compare and contrast the two pathways and explain why Expanded Access is preferable to Right to Try, both for patients and for the companies whose investigational products will be involved in such “compassionate use” attempts. She will underscore that the existence of such regulatory pathways are necessary but far from sufficient for patients to be able to use experimental medical products outside of clinical trials and highlight what other obstacles, real and perceived, reasonable and unreasonable exist. Alison Bateman-House, PhD, MPH, MA Assistant Professor, Division of Medical Ethics New York University Langone Medical Center Commentary by Robert Vonderheide, MD, DPhil John H. Glick Abramson Cancer Center Professor Perelman School of Medicine Class of 1962 Auditorium, John Morgan Building (3620 Hamilton Walk) Penn Medical Ethics
March
3
1402 Blockley Hall (423 Guardian Drive)

Penn Bioethics Seminar | Dominic A. Sisti, PhD

Learn More 2020-03-03 12:00:00 2020-03-03 13:00:00 America/New_York Penn Bioethics Seminar | Dominic A. Sisti, PhD Ethics in psychedelic psychiatry   Dominic A. Sisti, PhD Assistant Professor Medical Ethics and Health Policy University of Pennsylvania     1402 Blockley Hall (423 Guardian Drive) Penn Medical Ethics
See All Events

Loading tweets...